

## 4DMedical wins three-year commercial contract with UCSD Health

19 November 2024

### Highlights

- 4DMedical enters three-year commercial contract with UC San Diego (UCSD) Health for advanced lung imaging analysis
- UCSD Health is ranked among the top 10 hospitals in the U.S. for respiratory care
- Contract demonstrates the appeal of 4DMedical's comprehensive portfolio of structural and functional lung analysis tools for U.S. clinicians and their patients

**Melbourne, Australia, 19 November 2024:** 4DMedical Limited (ASX: 4DX) ("4DMedical" or the "Company"), a leading innovator in respiratory imaging technology, today announces the signing of a three-year commercial contract with UC San Diego Health. UC San Diego (UCSD) Health is ranked among the top 10 hospitals in the U.S. for respiratory care, and this agreement will enable its doctors to utilise 4DMedical's portfolio of advanced lung imaging products as part of clinical care.

### Commercial contract with UC San Diego Health

UCSD Health is an academic medical center (AMC) recognised in the U.S. for its cutting-edge research and excellence in clinical practice. AMCs play a significant role in the U.S. healthcare system by integrating a community hospital with a school of medicine. At UCSD Health, this means that many of its doctors are also faculty members at UCSD School of Medicine, conducting original research as well as treating patients. This blend of research, education, clinical expertise, and superior resources, means that AMCs are often early adopters of new technology and influential across the broader U.S. healthcare system, making them important sites for companies like 4DMedical.

This 3-year commercial contract is therefore a significant achievement for the Company, offering compelling validation of the diagnostic capabilities and clinical relevance of its advanced lung imaging technology. While the terms of the contract are commercial-in-confidence, UCSD Health will initially have access to 4DMedical's suite of CT-based products, with potential for this to expand across the entire 4DMedical portfolio.

### 4DMedical MD/CEO and Founder Andreas Fouras said:

Doing business with UCSD Health underscores the growing recognition of 4DMedical's innovative technology in transforming respiratory care. Not only are they a great customer for us, but their status as one of the best respiratory hospitals in the country will undoubtedly boost our commercialisation efforts with the broader U.S. healthcare system.

We have an incredibly busy end to the year, including RSNA in early December. I look forward to updating you on that, and other commercial activity, over the coming weeks.

—ENDS—

Authorised by the 4DMedical Board of Directors.



## Contacts

### Corporate

Chief Financial Officer

Simon Glover

[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

### Administration

Company Secretary

Naomi Lawrie

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

## About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology<sup>®</sup>, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS<sup>®</sup>) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS<sup>™</sup>.

XV LVAS<sup>®</sup> and CT LVAS<sup>™</sup> reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity, and more personalised care for patients.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)

For personal use only